Dr Kim Wolff  
Senior Lecturer in the Addictions
Head IOP Postgraduate Taught Studies

Chair, IOP Teaching Committee

Chair, College Admissions Committee

biography

Senior lecturer in the Addictions. Main research interest is the pharmacokinetics of the opioid methadone and biological indicators of substance misuse. I am Programme Leader for the MSc in Clinical & Public Health Aspects of Addiction. As Head of Graduate Studies I have responsibility for the provision of postgraduate programmes at the IOP, as Head of Graduate Studies.

activities and interests

I have 5 PhD students investigating nicotine metabolism; methadone prescribing in pregnancy; addicted health care professionals; ecstasy profiling and; craving in co-dependence with alcohol and methadone.

I have funding from the Department of Transport to investigate the biological indicators of alcohol use.

I have developed a vibrant international masters degree prgoramme for those wishing to pursue a career in the Addictions.

teaching activities

Within the IOP and as Head of Graduate Studies I have overseen the introduction of a common credit framework and modularisation of all Taught Postgraduate programmes.

As Learning & Teaching Co-ordinator I have introduced the ’Statement of Teaching Proficiency’ to staff at the IOP and set up a Personal Tutor scheme.

As an expert in the Addictions I have acted as a consultant to many countries regarding the creation of taught programmes, including Slovenia, Jordan and Chile.

I am currently the King’s College lead for an international MSc programme in the Addictions, linking with Adelaide University and Virginia Commonwealth University.

I present workshops around the UK for professions working within or aligned to the addictions regarding the addiction behaviour and treatment options.

publications

1. K Wolff, EM Tsapakis, AR Winstock, D Hartley, D Holt, ML Forsling, KJ Aitchison. (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population, J Phychopharmacology, Special Edition, 20,[3] 400-410.
2. Wolff K, Boys A, Hay AWM, Raistrick D. (2005) Changes in Clearance during Pregnancy, Euro J Clin Pharmacol, 61:763-768. Online publication available October 29 2005;
3. Winstock A, Wolff K, Ramsey J. 4 –MTA (2002): A new synthetic drug on the dance scene. Drug & Alcohol Dependence, 67; 111-115.
4. Tacke U, Wolff K, Finch E, Strang J (2001). The effect of tobacco smoking on subjective symptoms of inadequacy ("not holding") amongst opiate addicts in methadone maintenance treatment. Addiction Biology, 6; 137-145.
5. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Ennis M, Silber E. Cannabis Use in Patients with Multiple Sclerosis. Multiple Sclerosis, Revision October 2005, In press March 2006
6. Wolff K & Winstock Ketamine: From medicine to misuse. Invited review, CNS Drugs, Reviewed proofs Nov 2005, Due out May 2006
7. Gross SR, Wolff K, Marshall EJ. Follow-up of provision of inpatient treatment for healthcare professionals with alcohol dependence: snapshot of a specialist NHS Service. J Substance Use & Misuse, September, Responding to referees Nov 2005.
8. Kamal, L Mitchell, TB, Lintzeris, N, Wolff, K. Clients’ perceptions of their reasons for leaving methadone maintenance treatment, European Addiction Research, Submitted July 2005.
9. Senbanjo, R, Wolff, K, Marshall JE. Excessive Alcohol Consumption is associated with reduced Quality of Life among Methadone Patients, Submitted Addiction March 2006
10. Wolff K. (2002) Characterisation of Methadone Overdose: Clinical considerations and the Scientific Evidence, Therapeutic Drug Monitoring, 24; 457-470.
11. Tacke U, Wolff K, Finch E, Strang J (2001). The effect of tobacco smoking on subjective symptoms of inadequacy ("not holding") amongst opiate addicts in methadone maintenance treatment. Addiction Biology, 6; 137-145.
12. Wolff K, Banbery J, Raistrick D. (2000) Dihydrocodeine; A useful tool in the detoxification of methadone maintained patients. Journal of Substance Misuse Treatment, 19, 301-305.
13. Wolff K, Rostami-Hodjegan A, Hay AWM, Raistrick, Calvert R, Tucker GT (2000). A drug prediction technique for methadone treatment. Addiction 95, 124-131.
14. Wolff K, Farrell M, Marsden J, Monteiro RA, Ali R, Welch S, Strang J (1999). A review of Biological Indicators of Illicit Drug Misuse, Practical Considerations and Clinical Usefulness, Addiction, 94, 1279 -1298.
15. Rostami-Hodjegan A, Wolff K, Hay AWM, Raistrick D, Calvert R, Tucker GT. (1999) Population pharmacokinetics in opiate users: characterisation of time-dependent changes. British Journal of Clinical Pharmacology, 47, 974-986.
16. Wolff K, Strang J. (1999) Therapeutic drug monitoring for methadone: scanning the horizon. European Addiction Research, 5, 36-42.
17. Wolff K, Rostami-Hodjegan A, Shires S, Feely M, Hay A, Calvert R, Raistrick D, Tucker GT. (1997) The pharmacokinetics of Methadone in healthy subjects and opiate users. British Journal of Clinical Pharmacology 44:325-334.

last updated: Tuesday, April 25, 2006